| 姚舒洋,张 毅.EGFR敏感突变PD-L1阳性晚期非小细胞肺癌治疗的研究进展[J].中国肿瘤,2021,30(4):309-312. |
| EGFR敏感突变PD-L1阳性晚期非小细胞肺癌治疗的研究进展 |
| Progress in Treatment of Advanced Non-small Cell Lung Cancer with EGFR Sensitive Mutation and PD-L1 Positive Expression |
| 中文关键词 修订日期：2020-10-21 |
| DOI：10.11735/j.issn.1004-0242.2021.04.A010 |
|
 |
| 中文关键词: 非小细胞肺癌 表皮生长因子受体 程序性死亡—配体1 靶向治疗 免疫治疗 |
| 英文关键词:non-small cell lung cancer epidermal growth factor receptor programmed cell death-ligand 1 targeted therapy immunotherapy |
| 基金项目:2017年度“扬帆”计划重点医学专业（XMLX201702） |
|
| 摘要点击次数: 1452 |
| 全文下载次数: 360 |
| 中文摘要: |
| 摘 要：临床前研究表明表皮生长因子受体（epidermal growth factor receptor，EGFR）酪氨酸激酶抑制剂和免疫检查点抑制剂可以协同消灭肿瘤细胞。有EGFR敏感突变同时程序性死亡—配体1（programmed cell death-ligand 1，PD-L1）阳性表达的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者可能是低毒高效的靶向药物联合免疫治疗的最佳受益者。该文从临床医生的角度，关注晚期EGFR敏感突变且有PD-L1阳性表达的NSCLC亚组患者。根据目前的临床证据，该文从诸多前瞻性临床试验结果到未来发展方向进行阐述，给临床治疗提供参考。 |
| 英文摘要: |
| Abstract：Preclinical studies have indicated that epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(TKIs) combined with immune checkpoint inhibitors(ICIs) can synergistically kill cancer cells. Therefore，it seems that advanced non-small cell lung cancer(NSCLC) patients with both EGFR sensitive mutation and programmed cell death-ligand1(PD-L1) positive expression may achieve greater benefits from these two low-toxicity and high-efficacy therapies. In this review the progress in treatment of this special group of patients based on the current evidence from the prospective clinical studies are elaborated，and the therapeutic strategies and related new drug development are discussed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |